Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
Our Science
For Investors +
Join Us

Press Releases

Year

May 16, 2023

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

March 28, 2023

Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients

March 15, 2023

Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old

March 14, 2023

Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis

February 21, 2023

Roivant Sciences Announces Change to its Board of Directors

February 13, 2023

Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update

February 2, 2023

Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares

February 1, 2023

Roivant Sciences Announces Proposed Public Offering of Common Shares

January 30, 2023

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023

January 4, 2023

Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2023 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn